Pfizer Sutent Review: Partial Response Could Mean Clinical Benefit In RCC Setting
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s decision to grant Pfizer’s Sutent a broad renal cell carcinoma claim suggests a consensus among reviewers that partial responses may be predictive of clinical benefit in RCC.
You may also be interested in...
Bristol Sprycel Cardiovascular Issues Not Enough To Prevent Accelerated Approval
QT prolongation appears to have been one of the primary safety considerations during FDA’s review of Bristol-Myers Squibb’s leukemia treatment Sprycel (dasatinib), review documents suggest.
Pfizer Sutent Potential Adrenal Toxicity Concern Surfaced Early In FDA Review
Review documents for Pfizer's Sutent show early, pre-NDA concern within FDA's oncology division relating to the multi-targeted tyrosine kinase inhibitor's potential to cause adrenal toxicity
Bayer/Onyx Nexavar FDA Review Shows Debate Over Full Vs. Subpart H Approval
Review documents for Bayer/Onyx’ Nexavar show disagreement within FDA regarding whether to grant the advanced renal cell carcinoma agent full or accelerated approval.